Data science in early drug discovery – getting it right from the start The application of data science in the early stages of drug development is not new – progress in algorithms and […] November 24, 2022 · Janssen Pharmaceutica
Cancer vaccines: not only treating tumors, but preventing them too The COVID-19 pandemic has brought vaccines back into the drug development spotlight, and mRNA vaccines are stealing the show with […] November 23, 2022 · V-Bio Ventures
New personalized cancer vaccine in the making thanks to unique Belgian collaboration The young Belgian start-up Persomed is unique – it was founded in 2020 by four partners each with relevant expertise […] November 23, 2022 · BioVox
Marfan patients team up with researchers to catch their silent killer The world’s undiagnosed Marfan patients often go through life unaware of the hidden killer lurking in their DNA – a […] November 23, 2022 · SciMingo
Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia Diepenbeek, Belgium, 15 November 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, […] November 15, 2022 · Quality by Design - Business & Communications
Is Belgium becoming a hub for gene therapy? Ghent, Belgium, 10 November 2022 – Gene therapy provides solutions to deadly diseases. Is the technology ready for a big […] November 10, 2022 · Quality by Design - Business & Communications
Intressa Vascular secures EUR 18 million in financing to support the development of its multilayer Allay™ Aortic Stent for the treatment of aortic dissection Intressa Vascular is using its proprietary stent braiding technology to develop an innovative multilayer stent for the treatment of aortic […] October 25, 2022 · Quality by Design - Business & Communications
Gene therapy challenges and the solutions in sight Dr. Federico Mingozzi is the CSO of Spark Therapeutics, the company behind Luxturna – the world’s first FDA-approved gene therapy […] October 19, 2022 · BioVox
We need more food and agtech start-ups – and we need them now! How are we going to feed an expected 10 billion people by 2050 in a sustainable way? It is a […] October 19, 2022 · V-Bio Ventures
Picking up early signals: SPINOVIT to prevent cardiovascular diseases with new monitoring method Preventing cardiovascular diseases before the first symptoms arise? That’s the ambition of SPINOVIT – a Louvain-La-Neuve company using a new […] October 19, 2022 · BioVox
BioVox: shining a light on Belgian biotech Beer, chocolate, and… biotech! When it comes to life sciences, Belgium excels. It consistently ranks as one of the world’s […] October 19, 2022 · BioVox
V-Bio Ventures leads Sibylla Biotech's EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases Ghent, Belgium, 4 October 2022 – V-Bio Ventures announces the successful close of a EUR 23 million Series A financing […] October 4, 2022 · V-Bio Ventures
NeuVasQ Appoints Former UCB Ventures VP and Partner Emmanuel Lacroix as Chief Executive Officer and Expands Its Board of Directors Gosselies, Belgium, 15 September 2022 – NeuVasQ Biotechnologies, a ULB spin-off developing pharmaceuticals to restore blood-brain barrier function, announces the […] September 20, 2022 · Quality by Design - Business & Communications
From pattern to patient: microbiome research needs to bridge the gap to the clinic The microbiome has been a trending scientific topic in recent years. Researchers have uncovered correlations between the human microbiome and […] September 7, 2022 · BioVox
VC opportunities for impact in the face of climate disaster Venture capitalists have a vital role to play in guiding our planet’s future. By investing in technological advances that remediate […] September 7, 2022 · V-Bio Ventures